The Implication of Cytogenetic Alterations in Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm Identified by Fluorescence <i>In Situ</i> Hybridization and Their Potential Diagnostic Utility
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated chromosomal aberrations in patients with pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) by fluorescence in situ hybridization (FISH) to identify cytogenetic changes and molecular markers that may be useful for preoperative diagnosis. Methods: Tissue samples from 48 PDAC and 17 IPMN patients were investigated by FISH analysis using probes targeting chromosomes 7q, 17p, 18q, 20q, and 21q and the pericentromeric region of chromosome 18 (CEP18). Results: The PDAC samples harbored 17p deletion (95.8%), 18q deletion (83.3%), CEP18 deletion (81.2%), 20q gain (81.2%), 21q deletion (77.1%), and 7q gain (70.8%). The IPMN samples had 17p deletion (94.1%), CEP18 deletion (94.1%), 21q deletion (70.6%), 18q deletion (58.8%), 20q gain (58.8%), and 7q gain (58.8%). A significant difference in CEP18 gain was identified between the PDAC and IPMN groups (p=0.029). Detection of 17p or 18q deletion had the highest diagnostic accuracy (80.0%) for PDAC. Conclusions: Chromosomal alterations were frequently identified in both PDAC and IPMN with similar patterns. CEP18 gain and 17p and 18q deletions might be involved in the later stages of PDAC tumorigenesis. Chromosome 17p and 18q deletions might be excellent diagnostic markers.
Abstract
Background/Aims: We investigated chromosomal aberrations in patients with pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) by fluorescence in situ hybridization (FISH) to identify cytogenetic changes and molecular markers that may be useful for preoperative diagnosis. Methods: Tissue samples from 48 PDAC and 17 IPMN patients were investigated by FISH analysis using probes targeting chromosomes 7q, 17p, 18q, 20q, and 21q and the pericentromeric region of chromosome 18 (CEP18). Results: The PDAC samples harbored 17p deletion (95.8%), 18q deletion (83.3%), CEP18 deletion (81.2%), 20q gain (81.2%), 21q deletion (77.1%), and 7q gain (70.8%). The IPMN samples had 17p deletion (94.1%), CEP18 deletion (94.1%), 21q deletion (70.6%), 18q deletion (58.8%), 20q gain (58.8%), and 7q gain (58.8%). A significant difference in CEP18 gain was identified between the PDAC and IPMN groups (p=0.029). Detection of 17p or 18q deletion had the highest diagnostic accuracy (80.0%) for PDAC. Conclusions: Chromosomal alterations were frequently identified in both PDAC and IPMN with similar patterns. CEP18 gain and 17p and 18q deletions might be involved in the later stages of PDAC tumorigenesis. Chromosome 17p and 18q deletions might be excellent diagnostic markers.
참고문헌 (33)
- Rahib L, "Projecting cancer incidence and deaths to 2030 : the unexpected burden of thyroid, liver, and pancreas cancers in the United States", Cancer Res, 74, pp.2913~2921 (2014)
- Ansari D, "Update on the management of pancreatic cancer : surgery is not enough", World J Gastroenterol, 21, pp.3157~3165 (2015)
- Notta F, "A genetic roadmap of pancreatic cancer : still evolving", Gut, 66, pp.2170~2178 (2017)
- Griffin CA, "Consistent chromosome abnormalities in adenocarcinoma of the pancreas", Cancer Res, 55, pp.2394~2399 (1995)
- Loukopoulos P, "Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma : identification of genetic indicators that predict patient outcome", Cancer Sci, 98, pp.392~400 (2007)
- Griffin CA, "Chromosome abnormalities in pancreatic adenocarcinoma", Genes Chromosomes Cancer, 9, pp.93~100 (1994)
- Schleger C, "Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization(CGH)", J Pathol, 191, pp.27~32 (2000)
- Kowalski J, "Chromosomal abnormalities of adenocarcinoma of the pancreas : identifying early and late changes", Cancer Genet Cytogenet, 178, pp.26~35 (2007)
- Adsay NV, "Utility of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma", Pancreas, 18, pp.111~116 (1999)
- Fritz S, "Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma", Ann Surg, 249, pp.440~447 (2009)
- Fujii H, "Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas", Am J Pathol, 151, pp.1447~1454 (1997)
- Miyabe K, "Locus", chromosome aberrations in intraductal papillary mucinous neoplasms analyzed by fluorescence in situ hybridization, 2015, pp.39, 512~520
- Soldini D, "Progressive genomic alterations in intraductal papillary mucinous tumours of the pancreas and morphologically similar lesions of the pancreatic ducts", J Pathol, 199, pp.453~461 (2003)
- Lee YN, "Core biopsy needle versus standard aspiration needle for endoscopic ultrasound-guided sampling of solid pancreatic masses : a randomized parallel-group study", Endoscopy, 46, pp.1056~1062 (2014)
- Sur YK, "Comparison of ultrasound-guided core needle biopsy and endoscopic ultrasound-guided fine-needle aspiration for solid pancreatic lesions", J Ultrasound Med, 34, pp.2163~2169 (2015)
- Barr Fritcher EG, "An optimized set of fluorescence in situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples", Gastroenterology, 149, pp.1813~1824 (2015)
- Fritcher EG, "A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures", Gastroenterology, 136, pp.2180~2186 (2009)
- Smoczynski M, "Routine brush cytology and fluorescence in situ hybridization for assessment of pancreatobiliary strictures", Gastrointest Endosc, 75, pp.65~73 (2012)
- Kipp BR, "A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures", Am J Gastroenterol, 99, pp.1675~1681 (2004)
- Gonda TA, "Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures", Gastrointest Endosc, 75, pp.74~79 (2012)
- Yamano M, "Genetic progression and divergence in pancreatic carcinoma", Am J Pathol, 156, pp.2123~2133 (2000)
- Adsay V, "Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract : recommendations of Verona Consensus Meeting", Ann Surg, 263, pp.162~177 (2016)
- American Joint Committee on Cancer (AJCC), "AJCC Cancer Staging Manual", pp.241~249 (2010), Springer
- Ciolino AL, "Statistical treatment of fluorescence in situ hybridization validation data to generate normal reference ranges using Excel functions", J Mol Diagn, 11, pp.330~333 (2009)
- Lüttges J, "Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis", Am J Pathol, 158, pp.1677~1683 (2001)
- Wilentz RE, "Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia : evidence that DPC4 inactivation occurs late in neoplastic progression", Cancer Res, 60, pp.2002~2006 (2000)
- Bardeesy N, "Pancreatic cancer biology and genetics", Nat Rev Cancer, 2, pp.897~909 (2002)
- 윤유석, "형광 동소 보합법을 이용한 췌장암의 세포유전학적 변화에 대한 분석과 그 임상적 의의", 한국간담췌외과학회지, 12(1), pp.75~85 (2008), 한국간담췌외과학회
- Iacobuzio-Donahue CA, "Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas : comparison with conventional ductal adenocarcinomas", Am J Pathol, 157, pp.755~761 (2000)
- Van Dyke D, "+18 or trisomy 18 in lymphoproliferative disorders", Atlas Genet Cytogenet Oncol Haematol, 7, pp.274~276 (2003)
- Gutiérrez ML, "Altered interphase fluorescence in situ hybridization profiles of chromosomes 4, 8q24, and 9q34 in pancreatic ductal adenocarcinoma are associated with a poorer patient outcome", J Mol Diagn, 16, pp.648~659 (2014)
- Stoecklein NH, "Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma", J Clin Oncol, 22, pp.4737~4745 (2004)
- Kipp BR, "Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization : a molecular test with proven clinical success", Cancer Cytopathol, 121, pp.610~619 (2013)